Bibliography
- DIOKNO AC, BROWN MB, BROOK BM et al. Clinical and cystometric characteristics of continent and incontinent noninstitutionalized elderly. J. Urol. (1988) 140(3):567–571.
- Incontinence. Causes, management and provision ofservices. A working party of the Royal College of Physicians. J. Royal Coll. Physic. London (1995) 29(4)272–274.
- ANDERSSON K-E: Current concepts in the treatment ofdisorders of micturition. Drugs (1988) 35:477–494.
- THUROFF J, BUNKE B, EBNER A et al.: Randomized,double-blind, multicenter trial on treatment of frequency, urgency, and incontinence related to detrusor hyperactivity. Oxybutynin versus propan-theline versus placebo. J. Urol. (1991) 145:813–817.
- OUSLANDER JG, BLAUSTEIN J, CONNOR A et al.: Pharma-cokinetics and clinical effects of oxybutynin in geriatric patients. J. Urol. (1988) 140:47–50.
- APPELL RA: Oxybutynin: the clinical experience. Contemp. Urol. (1991) 3:60–64.
- KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S,HILL S: Anticholinergic therapy: the need for continued surveillance. Neurourol. Urodyn. (1994) 13:432–433.
- STAHL MM, EKSTROM B, SPARF B et al: Urodynamic andother effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol. Urodyn. (1995) 14(6):647–655.
- NILVERBRANT L, HALLEN B, LARSSON G: Tolterodine: a new bladder selective, muscarinic receptor antago-nist: pre-clinical pharmacologic and clinical data. Life ScL (1997) 60:1129–1136.
- ••This is an article that reviews the pharmacologic propertiesof tolterodine.
- NILVEBRANT L, ANDERSSON K-E, GILLBERG P-G et al.: Tolterodine-a new bladder-selective antimuscarinic agent. Eur. J. Pharm. (1997) 327:195–207.
- ••This article reviews the pharmacologic properties oftolterodine and helps explain its clinical usefulness.
- CAULFIELD MP: Muscarinic receptor- characterization,coupling and function. PharmocoL Ther. (1993) 58:319–379.
- HULME EC, BIRDSALL NJM, BUCKLEY NJ et al.: Muscar-inic receptor subtypes. Annu. Rev. Pharmacol Toxicol (1990) 30:633–673.
- WANG P, LUTHIN GR, RUGGIERI MR: Muscarinic acetyl-choline receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol. Exp. Ther. (1995) 273:959–966.
- HEGDE SS, CHOPPIN A, BONHAUS D et al.: Functionalrole of M2-M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharm. (1997) 12(8):1409–1418.
- BRYNNE N, STAHL MM, HALLEN B et al.: Pharmacoki-netics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int. J. Chn. Pharmocol. Ther. (1997) 35 (7):287–295.
- BRYNNE N, DALEN P, ALVAN G et al.: Influence ofCYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin. Pharmacol. Ther. (1998) 63:529–539.
- POSTLIND H, DANELSON A, LINDGREN A et al.:Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Met. Disp. (1998) 26:289–293.
- NILVEBRANT L, GILLBERG PG, SPARF B: Antimuscarinicpotency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol. Toxicol. (1997) 81 (4) :169–172.
- VAN KERREBROECK PE, AMARENCO G, THUROFF JW etal: Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurol. Urodyn. (1998) 17 (5) :499–512.
- RENTZHOG L, STANTON SL, CARDOZO L et al: Efficacyand safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br. J. Urol. (1998) 81:42–48.
- APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 50:90–96.
- ••This is an excellent article that reviews the various clinicaltrials that have been performed using tolterodine.
- ABRAMS P, FREEMAN R, ANDERSTROM C et al.: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. (1998) 81 (6):801–810.
- •This article describes one of the clinical studies performed involving this new antimuscarinic.
- JONAS U, HOFNER K, MADERSBACHER H, HOLMDAHL TH: Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J. Urol. (1997) 15 (2) :144–151.
- •This is another article involving a clinical study of tolterodine versus placebo.